ADVANCED GASTRIC CANCER

This early-stage trial tests a new treatment for advanced stomach cancer that has not responded to standard therapies. It combines a vaccine made from the patient's own tumor mutations with specially grown immune cells. The main goal is to see if the combination is safe and can s…

This study tests a new combination of drugs (iparomlimab and tuvonralimab, called QL1706) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if the combo can shrink tumors and control the disease…

This study tests whether a diet low in leucine (an amino acid) can make chemotherapy and immunotherapy work better for people with advanced stomach cancer. About 73 adults aged 18-70 will follow this special diet alongside standard treatment. Researchers hope the diet will help s…

This study tests whether adding extra drugs to standard chemo-immunotherapy can help people with advanced stomach cancer. About 78 adults with non-surgical or metastatic stomach cancer will receive SHR1701 plus chemotherapy, along with either an EZH2 inhibitor or an anti-angiogen…

This study tests a new drug, SHR2554, combined with other cancer treatments for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if the combination is safe and helps shrink tumors or slow the dise…

This study tests a combination of two drugs—disitamab vedotin and tucatinib—for people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combo is safe and can shrink or control tumors. About 172 adults with these cancers who have a…

This early-phase study tests a new experimental drug called BGB-53038 in people with advanced or metastatic solid tumors that have a specific genetic change (KRAS mutation or amplification). The drug is a pan-KRAS inhibitor, meaning it aims to block many forms of the faulty KRAS …

This study tests whether a digital health platform, which includes a symptom-tracking app and a structured telenursing program, can help cancer patients better manage chemotherapy side effects and improve their quality of life. About 414 adults with early or advanced gastric, lun…

This study enrolls 400 adults with advanced breast, stomach, bladder, or lung cancer who are receiving a type of targeted therapy called an antibody-drug conjugate (ADC). Researchers will compare tumor samples taken before and after treatment to identify genetic or molecular chan…